Testing ARNI in people with implanted LVAD devices
Treatments studied
Part of Heart & circulation clinical trials.
This trial studies whether a heart medicine called ARNI (sacubitril-valsartan) is safe and works well for people who have a durable LVAD and moderate-to-severe heart pumping weakness. It may help improve symptoms and outcomes, while carefully checking side effects in this higher-risk group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have a durable LVAD (a long-term heart pump implanted)
- Your heart failure symptoms are NYHA class II, III, or IV
- Your heart pumping strength (LVEF) is under 40%
- You can and agree to sign informed consent
- You can follow the study rules and visit schedule
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a treatment called SCD is safe and workable in people who have worsening heart failure along with kidney problems, and who are waiting to get an LVAD (a mechanical heart pump). It is mainly a feasibility study, meaning the researchers want to see if this approach can be used in real hospital care and monitor effects on key health measures.
This study tests whether a medication called sacubitril/valsartan can improve the heart's ability to relax and fill with blood (diastolic function) in people with heart failure with reduced ejection fraction. It may help improve your heart function and overall well-being.
This study tests a medication that may help people with a specific type of heart disease (ATTR amyloidosis) and heart failure with reduced pumping function. The treatment could slow disease progression and improve symptoms.
This trial compares two blood-pressure and heart-failure medicines: sacubitril/valsartan versus ramipril, to see which improves heart pumping and heart structure over time. It’s aimed at people with ischemic (blocked-artery) heart failure with mid-range ejection fraction and ongoing symptoms.
This trial tests a combination of three heart failure drugs (ARNI, SGLT2i, MRA) to see if they improve symptoms and outcomes in people with a type of heart failure where the heart pumps normally but doesn't relax properly (HFpEF).
This trial tests a drug called sacubitril/valsartan to see if it helps people who have both a prosthetic heart valve and heart failure with a weak heart pump. The goal is to improve heart function and symptoms.
Hear when a new Stage D Heart Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.